With the introduction of the anti-CD20 monoclonal antibody rituximab, B-cell non-Hodgkin lymphoma was the first malignancy successfully treated with an immunotherapeutic agent. Since then, numerous advances have expanded the repertoire of immunotherapeutic agents available for the treatment of a variety of malignancies, including many lymphoma subtypes. These include the introduction of monoclonal antibodies targeting a variety of cell surface proteins, including the successful targeting of immunoregulatory checkpoint receptors present on T-cells or tumour cells. Additionally, cellular immunotherapeutic approaches utilize T- or Natural Killer-cells generated with chimeric antigen receptors against cell surface proteins or Epstein-Barr virus-associated latent membrane proteins. The following review describes the current state of immunotherapy for non-Hodgkin lymphoma including a summary of currently available data and promising agents currently in clinical development with future promise in the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
CITATION STYLE
Barth, M. J., Chu, Y., Hanley, P. J., & Cairo, M. S. (2016, May 1). Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. British Journal of Haematology. Blackwell Publishing Ltd. https://doi.org/10.1111/bjh.14078
Mendeley helps you to discover research relevant for your work.